Non-GMP CDMO Services
We design and serve plasmids, vectors,
and viruses for AAV
gene therapy programs from researchers
to bio-pharmas around the world.
팝업레이어 알림
PREV
NEXT
SCROLL
PIPELINE
| Candidate | Indication | Development status | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|||
| Neuro-Degenerative Disorder | ANL-101 | Alzheimer´s Disease |
In Vivo
|
|||
| ANL-102 | MCI |
In Vitro
|
||||
| Rare Genetic Disease | ANL-301 | Lafora disease |
In Vivo
|
|||
| ANL-302 | Undisclosed |
In Vitro
|
||||
| ANL-303 | ALS |
In Vitro
|
||||
| ANL-304 | Fronto Temporal Dementia |
In Vivo
|
||||
좌우로 스크롤 하시면 전체 내용을 확인할 수 있습니다.
NOTICE
VIEW MORE
-
NOTICE
2021-01-19
ANL-104, a treatment for degenerative obesity and diabetes, registered as a domestic patent
The domestic patent registration of ANL-104, a candidate substance for the treatment of degenerative metabolic diseases of ANLBIO Co., Ltd., was decided on January 15.'ANL-104' is a gene therapy that promotes body fat decomposition by enhancing the expression of target proteins in a way that inhibits certain microRNAs (microRNAs) that increase with aging, and is currently in the preclinical stage as a major indication of degenerative obesity and diabetes.Target proteins that increase expression by administration of 'ANL-104' are known to have excellent lipolysis effects. Through animal experiments conducted with external specialized institutions, the company confirmed that the treatment injected into the hypothalamus increased the expression of the protein, significantly reducing fat as well as weight and blood sugar, and this registered patent was filed in 2017 based on the above results of these animal tests. With the completion of the domestic patent registration of ANL-104, a candidate for degenerative obesity and diabetes treatment, along with ANL-101, which was selected as a dementia treatment project by the Dementia Overcoming Research and Development Project in December, it is expected to gain further momentum. Given the rapidly aging population structure, the company's medical demand for degenerative diseases such as dementia, obesity, and diabetes is expected to increase sharply in the future.We will make efforts to help ANLBIO advance the treatment of dementia diseases such as Alzheimer's disease and Parkinson's disease, as well as numerous diseases that hinder the quality of life with age, such as degenerative metabolic diseases of ANL-104.
-
NOTICE
2021-01-19
ANL-101, Selection of Non-clinical Support Tasks for Development of Dementia Treatment by the Dementia Overcoming Research and Development Project Group
ANL-101, a candidate substance for Alzheimer's disease treatment by A&L Bio Co., Ltd., has been selected as a non-clinical task in the field of dementia treatment development by the Dementia Overcoming Research and Development Project Group (Director Muk In-hee).The research project, the first of its kind since the launch of the Dementia Overcoming Research and Development Group (hereinafter referred to as the "Project Group") under the Ministry of Health and Welfare and the Ministry of Science and ICT, is a national project directly linked to the national dementia over nine years. According to the selection of this support project, a total of 1 billion won in R&D expenses for non-clinical research and development of ANL-101 will be executed by 2023.A total of 190 companies reportedly applied for i) dementia development mechanisms, ii) dementia prediction and diagnosis, iii) dementia prevention and treatment technology development projects, and 58 tasks were supported by ANLBIO's selected dementia treatment development cost clinical tasks. In particular, the non-clinical section of dementia treatment has the highest competition rate of about 20 to 1, and ANLBIO is the only private bio company to be selected.The evaluation and selection of this project was conducted in a way that national research institutes, industry-academic cooperation groups, large hospitals, and bio companies that applied to different fields were cross-evaluated, and a very objective evaluation was made. Given that ANL-101 was selected according to the above objective evaluation procedure for the national project to overcome dementia, the technological progress and originality of ANLBIO, which is developing a treatment for Alzheimer's disease, has been confirmed through a new approach.With the selection of this assignment, all ANLBIO executives and employees will work harder to help patients and their families who are still suffering from Alzheimer's disease find a healthy daily life as soon as possible.
NEWS
VIEW MORE
-
NEWS
2022-12-20
ANLBIO-ToolGen, Joint R&D contract for treatment of progeria
ANLBIO-ToolGen, Joint R&D contract for treatment of progeria ▲ Kim Young-ho, CEO of ToolGen (left), and Moon Hong-sung, CEO of ANLBIOToolGen gene editing platform utilizes AAV technology from ANLBIOToolGen announced on the 20th that it has signed a joint research and development agreement with ANL BIO to develop progeria gene therapy.View the original articleYoon So-young, a bio-speculatorsoyoung.yoon@bios.co.kr<Copyright holder © Prohibition of unauthorized reproduction and redistribution of biospectors>
-
NEWS
2022-01-20
Signs an MOU with Medisapiens to develop new drugs based on AI
▲Moon Hong-sung, CEO of ANLBIO (left), Kang Sang-gu, CEO of Medysapiens (right)ANLBIO, which is developing ANAV (Adeno-Associated Virus) vector-based gene therapy targeting degenerative central nervous system (CNS) diseases and rare diseases, announced on the 18th that it has signed a business agreement with MedySapiens (MGS) to develop a genetic rare disease diagnosis solution using artificial intelligence (AI).According to the announcement, ANLBIO will collaborate with Medicine to find biomarkers and treatment targets related to the diagnosis and prognosis of degenerative brain diseases (such as Alzheimer's disease and Parkinson's disease). In addition, ANLBIO explained that it plans to start developing gene therapy as a target for rare diseases obtained through this collaboration.Moon Hong-sung, CEO of ANLBIO, said, "With many people suffering from degenerative diseases due to the global aging society, developing biomarkers for clinical use in clinical trials for Alzheimer's disease and Parkinson's disease is a crucial task."Kang Sang-gu, CEO of MedySapiens, said, "Through a joint study with ANLBIO, technology using its artificial intelligence platform will be able to be the best tool for developing various treatments through the convergence of artificial intelligence and bio technology."
TOP